Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DGAP-PVR : Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

07/26/2021 | 10:58am EDT
DGAP Voting Rights Announcement: Evotec SE 
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the 
objective of Europe-wide distribution 
2021-07-26 / 16:57 
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Notification of Major Holdings 
1. Details of issuer 
 
 
 Name:                          Evotec SE 
 
 Street:                        Manfred Eigen Campus / Essener Bogen 7 
 
 Postal code:                   22419 
 
 City:                          Hamburg 
                                Germany 
 
 Legal Entity Identifier (LEI): 529900F9KI6OYITO9B12 
 2. Reason for notification 
 
 
 X             Acquisition/disposal of shares with voting rights 
 
               Acquisition/disposal of instruments 
 
               Change of breakdown of voting rights 
 
               Other reason: 
 3. Details of person subject to the notification obligation 
 
 
 Legal entity: Impax Asset Management Group plc 
 City of registered office, country: London, United Kingdom 
 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 
 
 
 
 5. Date on which threshold was crossed or reached: 
 
 
 23 Jul 2021 
 6. Total positions 
 
 
                       % of voting rights % of voting rights through     Total of 
                       attached to shares                instruments    both in %        Total number of voting rights 
                          (total of 7.a.)   (total of 7.b.1 + 7.b.2)      (7.a. +             pursuant to Sec. 41 WpHG 
                                                                            7.b.) 
 
 New                               3.02 %                     0.00 %       3.02 %                            164608236 
 
 Previous                           n/a %                      n/a %        n/a %                                    / 
 notification 
 7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG) 
 
 
 ISIN                    Absolute                        In % 
 
                       Direct       Indirect         Direct       Indirect 
               (Sec. 33 WpHG) (Sec. 34 WpHG) (Sec. 33 WpHG) (Sec. 34 WpHG) 
 
 DE0005664809               0        4966723         0.00 %         3.02 % 
 
 Total                    4966723                       3.02 % 
 b.1. Instruments according to Sec. 38 (1) no. 1 WpHG 
 
 
 Type of instrument Expiration or maturity date Exercise or conversion       Voting rights absolute Voting rights in % 
                                                period 
 
                                                                                                  0             0.00 % 
 
                                                Total                                             0             0.00 % 
 b.2. Instruments according to Sec. 38 (1) no. 2 WpHG 
 
 
 Type of        Expiration or maturity Exercise or conversion  Cash or physical            Voting rights  Voting rights 
 instrument     date                   period                  settlement                       absolute           in % 
 
                                                                                                       0         0.00 % 
 
                                                               Total                                   0         0.00 % 
 8. Information in relation to the person subject to the notification obligation 
 
 
               Person subject to the notification obligation is not controlled nor does it control any other 
               undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.). 
 
 X             Full chain of controlled undertakings starting with the ultimate controlling natural person or legal 
               entity: 
 
 
 
 Name                      % of voting rights (if at   % of voting rights through instruments     Total of both (if at 
                                   least 3% or more)                 (if at least 5% or more)        least 5% or more) 
 
 Impax Asset Management                            %                                        %                        % 
 Group plc 
 
 Impax Asset Management                            %                                        %                        % 
 Limited 
 
 -                                                 %                                        %                        % 
 
 Impax Asset Management                            %                                        %                        % 
 Group plc 
 
 Impax Asset Management                            %                                        %                        % 
 (AIFM) Limited 
 9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting: 
 
 
  Proportion of voting rights Proportion of instruments Total of both 
 
                            %                         %             % 
 10. Other explanatory remarks: 
 
 
 Impax Asset Management Group plc is the parent entity of Impax Asset Management Limited and Impax Asset Management 
 (AIFM) Limited and does not control any of the shares. Impax Asset Management Limited and Impax Asset Management 
 (AIFM) Limited are investment managers with delegated voting rights on behalf of managed portfolios. 
 Date 
 
 
 26 Jul 2021 
 ----------------------------------------------------------------------------------------------------------------------- 

2021-07-26 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Internet:     www.evotec.com 
 
End of News   DGAP News Service 
=------------ 

1221713 2021-07-26

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1221713&application_name=news 
 

(END) Dow Jones Newswires

July 26, 2021 10:57 ET (14:57 GMT)

All news about EVOTEC SE
09/15EVOTEC : publishes DDup 11 – AI-driven antibody discovery at Evotec
PU
09/06EVOTEC PARTNER BAYER : Phase IIb trial shows eliapixant significantly decreases ..
PU
09/02KAZIA THERAPEUTICS : Evt801 phase i study receives full regulatory approval
AQ
09/02EVOTEC : and Secarna Pharmaceuticals expand strategic partnership in the field o..
PU
09/02PRESS RELEASE : Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals a..
DJ
09/02Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field ..
CI
09/02KAZIA THERAPEUTICS : Secures French Regulatory Approval for Phase 1 Trial of Can..
MT
09/02EVOTEC : partner Kazia Therapeutics announces full regulatory approval for Phase..
PU
09/02EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..
PU
09/02EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..
EQ
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 564 M 664 M 664 M
Net income 2021 74,0 M 87,1 M 87,1 M
Net Debt 2021 61,0 M 71,8 M 71,8 M
P/E ratio 2021 99,0x
Yield 2021 -
Capitalization 7 428 M 8 739 M 8 745 M
EV / Sales 2021 13,3x
EV / Sales 2022 11,6x
Nbr of Employees 3 914
Free-Float 87,1%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 45,06 €
Average target price 40,01 €
Spread / Average Target -11,2%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Iris Löw-Friedrich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE48.81%8 739
MODERNA, INC.321.80%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.43.91%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-12.32%27 670